Why It Matters
Medical device giant Medtronic disclosed $1.18 million in lobbying expenditures for the second quarter of 2026, according to a filing submitted July 21.
By the Numbers
Medtronic's increased $240,000 from its $940,000 disclosed in the quarter one 2026 filing.
Broader Context
Medtronic's in-house lobbying effort comes as the regulatory landscape for medical devices continues to shift. In April, the Centers for Medicare and Medicaid Services and the Food and Drug Administration jointly unveiled the RAPID pathway, designed to compress the gap between FDA authorization and Medicare national coverage from over a year to as little as two months for certain Class II and Class III breakthrough devices. The streamlined approval process could significantly affect how Medtronic and other device makers bring innovations to market and secure reimbursement.
Medtronic's quarter two lobbying expenditures were handled entirely through in-house government affairs staff. The company's lobbying team includes Kristina Pisanelli, Vice President and Head of Global Government Affairs; Senior Directors Todd Gillenwater, Andrea Looney, and Jessica Battaglia; and other internal resources.
The Bottom Line
Medtronic's healthcare company lobbying filing reflects the ongoing importance of government relations for major device makers navigating FDA policy, reimbursement rules, and broader healthcare legislation.
Access the Legis1 platform for comprehensive political news, data, and insights.
Spot something wrong? Report an issue with this article